Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : DBPR112
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : National Health Research Institutes
Deal Size : Not Applicable
Deal Type : Not Applicable
AnBogen Therapeutics Receives Approval from U.S. FDA for Phase Ib/II Protocol Amendment for ABT-101
Details : ABT-101 (DBPR112) demonstrates excellent therapeutic potential and superior safety profile compared to competitors that are under clinical development. It meets challenges of unmet medical needs for cancer drugs targeting exon 20 insertions in HER2.
Brand Name : ABT-101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 13, 2022
Lead Product(s) : DBPR112
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : National Health Research Institutes
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?